RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals 2020/12/10 01:57:37 Investing.com
RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals
Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years 2020/11/27 08:00:00 Business Wire
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for SYMKEVI® (tezacaftor/ivacaftor) with KALYDECO® (ivacaftor), to include the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or one copy of the F508del mutation and one copy of one of 14 mutations
Odds Of Vertex's Pipeline Success Aren't Dismal As Some Fear, Bernstein Says 2020/11/20 15:45:07 Benzinga
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) shares have come under selling pressure recently, given investor concern regarding diversity in the pipeline for this cystic fibrosis-focused biopharma. The Vertex Analyst: Bernstein analyst Analyst Vincent Chen initiated coverage of Vertex with an Outperform rating and $275 price target. The Vertex Thesis: Vertex's pipeline is underappreciated and offers substantial upside optionality, Chen said in a note. The cystic fibrosis franchise could reach sales of about $10 billion by 2025, with patent exclusivity into the late 2030s and strong potential for lifecycle … Full story available on Benzinga.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Earns Outperform Rating from Analysts at Sanford C. Bernstein 2020/11/20 13:32:45 Transcript Daily
Sanford C. Bernstein started coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report issued on Friday, The Fly reports. The brokerage set an “outperform” rating and a $275.00 price target on the pharmaceutical company’s stock. Sanford C. Bernstein’s target price suggests a potential upside of 29.74% from the stock’s current price. A number […]
Cystic fibrosis drug Trikafta could change lives - if Health Canada approves it 2020/11/18 09:00:00 CBC News
After a year of hesitation in the face of pending cost control guidelines, Vertex Pharmaceuticals has submitted Trikafta to Health Canada for approval - now the hard work begins, writes Jeremie Saunders.
Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators 2020/09/24 09:25:00 Business Wire
BOSTON--(BUSINESS WIRE)-- #ECFS2020--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA
GOLDMAN SACHS: Buy these 21 stocks on track for years of market-beating growth that could make them future giants — even rivals to the FAANGs 2020/09/20 11:49:00 Business Insider
Summary List Placement These days it's hard to picture a stock market that isn't dominated by Big Tech. But two decades ago, who imagined a market where GE and Exxon were almost afterthoughts? The amount of money invested in Apple, Amazon, Microsoft, Alphabet, and Facebook today is staggering, as Goldman Sachs Chief US Equity Strategist David Kostin says the stock market hasn't been this top-heavy in 40 years. But it will change one day, and Kostin says people are hungry for the next big thing. "Investors are increasingly searching for fast-growing firms beyond the 'current five,'" he wrote. Finding those potential replacements starts with a focus on the incredible growth that made those five companies so successful. "The ability of these firms to grow sales rapidly regardless of the economic situation has been brought into focus by the corona crisis," he said. "Growth is particularly important with interest rates at the lower bound. " So Kostin and his team applied their " Rule of Ten " framework and sought companies that reported annual revenue growth of at least 10% in 2018 and 2019, and are expected to maintain that level in 2021 and 2022.
Why One Analyst Thinks That Dell Is Undervalued 2020/09/19 01:32:00 Barron's
Also, Wall Street views on Sirius XM, Equinix, Aaron’s, Vertex Pharmaceuticals, IMAX, and First Republic Bank.
Big Tech Weighs Too Much on the S&P 500. Feast on These Stocks Instead. 2020/09/18 22:15:00 Barron's
The allure of Autodesk, Intuitive Surgical, PayPal, Vertex Pharmaceuticals, ServiceNow, and some small-cap funds. Also, Blackstone boss Steve Schwarzman’s take on the future of cities.
European advisory group backs expanded use of Vertex's Kalydeco (NASDAQ:VRTX) 2020/09/18 12:38:25 Seeking Alpha
The European Medicines Agency's advisory group CHMP has adopted a position opinion backing the use of Vertex Pharmaceuticals' (NASDAQ:VRTX) Kalydeco (ivaca
Vertex Pharmaceuticals reports 7.1% stake in Kymera Therapeutics 2020/09/03 20:44:09 Seeking Alpha
Vertex Pharmaceuticals (NASDAQ:VRTX) acquires ~3.15M shares of Kymera Therapeutics (NASDAQ:KYMR), representing 7.1% of its total shares outstanding. Shares
FDA accepts three supplemental applications from Vertex for expanded use of CF meds (NASDAQ:VRTX) 2020/09/01 13:22:43 Seeking Alpha
The FDA has accepted for review three supplemental marketing applications from Vertex Pharmaceuticals (NASDAQ:VRTX) seeking expanded labels for cystic fibr
Cystic fibrosis drug Kaftrio to be available on NHS after European licence granted 2020/08/21 17:40:06 The Guardian
UK health bodies already have deals in place with maker Vertex to secure access The European commission has licensed a new, potentially lifesaving drug to treat cystic fibrosis, meaning it will be available on the NHS to many who have the condition. The drug, Kaftrio, is produced by Vertex Pharmaceuticals and contains three key ingredients: tezacaftor, ivacaftor and elexacaftor. Continue reading…
Vertex Pharmaceuticals : Gets Europe OK for Kaftrio Combination in Cystic Fibrosis | MarketScreener 2020/08/21 13:32:01 MarketScreener
By Colin Kellaher Vertex Pharmaceuticals Inc. on Friday said the European Commission approved Kaftrio in combination with ivacaftor to treat people ages 12 and over with cystic fibrosis. … | August 21, 2020
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older 2020/08/21 13:07:00 Business Wire
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission (EC) has granted marketing authorization for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor to treat people with cystic fibrosis (CF) ages 12 years and older with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. For the firs